Origins – ICT Bradford
ICT established in 2005 to identify and research unique anticancer technologies.
4-storey purpose-built facility, over 50 research and oncologist specialists.
Multi-disciplinary approach covering drug design, synthesis, screening, pharmacology and Phase I clinical support.
Incanthera founded in 2010 through spin out from ICT to provide commercial outlet for IP technology and research projects.
10 year pipeline deal with ICT gives Incanthera first access to targeted prodrug therapeutics for the treatment of cancer.
Progressing anticancer medical research